(1S,4R)-2-氮杂双环[2.2.1]-5-庚烯-2-羧酸叔丁酯 | 702666-72-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (1S,4R)-2-氮杂双环[2.2.1]-5-庚烯-2-羧酸叔丁酯
• 英文名称: (-)-N-tert-butyloxycarbonyl-2-azabicyclo[2.2.1]hept-5-ene
• 英文别名: tert-butyl (1S,4R)-2-azabicyclo[2.2.1]heptan-5-en-2-carboxylate；tert-butyl (1S,4R)-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate；(1S,4R)-tert-butyl 2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate
• CAS: 702666-72-6
• 化学式: C₁₁H₁₇NO₂
• 分子量: 195.261
• InChiKey: ZATXHTCUZAWODK-DTWKUNHWSA-N

物化性质

• 沸点：
  259.6±29.0 °C(Predicted)
• 密度：
  1.104±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  (1S,4R)-2-氮杂双环[2.2.1]-5-庚烯-2-羧酸叔丁酯 在 sodium tetrahydroborate 、 18-冠醚-6 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 tert-butyl (1S,4S,5R)-5-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate
  参考文献：
  名称：

  EP3650449

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl (1S,2R,4S,5R,6R)-5-hydroxy-3-azatricyclo[2.2.1.02,6]heptane-3-carboxylate 以30%的产率得到(1S,4R)-2-氮杂双环[2.2.1]-5-庚烯-2-羧酸叔丁酯
  参考文献：
  名称：

  Organolithium-induced enantioselective alkylative double ring-opening of epoxides: synthesis of enantioenriched unsaturated amino alcohols

  摘要：

  The use of (-)-sparteine as an external chiral ligand in enantioselective organolithium-induced alkylative double ring-opening of dihydropyrrole epoxides and 7-azanorbornene-type epoxides gives unsaturated acyclic amino alcohols, and amino cyclohexenols in up to 87% ee. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.02.055

文献信息

• Sulfone derivatives as 5-HT7 receptor ligands
  申请人：——

  公开号：US20040229864A1

  公开（公告）日：2004-11-18

  The present invention relates to sulfone derivatives of formula (I): Ar—SO 2 —CR 2 R 3 -L-N(R 1 ) 2 I wherein Ar, L, R 1 , R 2 and R 3 are as defined herein, and pharmaceutically acceptable salts and N-oxides thereof, useful in the treatment of a condition which is susceptible to treatment by modulation of 5-HT 7 receptor activity, such as depression or a sleep disorder.

  本发明涉及式（I）的砜衍生物：Ar—SO2—CR2R3-L-N(R1)2I，其中Ar，L，R1，R2和R3如本文所定义，并且其药用盐和N-氧化物，用于治疗通过调节5-HT7受体活性可治疗的疾病，如抑郁症或睡眠障碍。
• Synthesis of 5- and 6- chloropyridyl-substituted 2-azabicyclo[2.2.1]heptanes; novel epibatidine isomers
  作者：John R. Malpass、Caroline D. Cox

  DOI：10.1016/s0040-4039(98)02624-0

  日期：1999.2

  A synthetic route to the epibatidine analogue endo-5-(6-chloro-3-pyridyl)-2-azabicyclo[2.2.1]heptane and the corresponding endo-6- isomer is described, starting from a readily-available 2-azabicyclo[2.2.1]hept-5-ene derivative. Both the exo-5- and exo-6- compounds are also shown to be accessible from the same substrate using reductive Heck chemistry.

  从易于获得的2-氮杂双环开始，描述了一种合成表异丁烷类似物的内部-5-（6-氯-3-吡啶基）-2-氮杂双环[2.2.1]庚烷和相应的内部-6-异构体的合成途径。[2.2.1]庚-5-烯衍生物。两个外型-5-和外-6-化合物也显示出是从使用还原的Heck化学在同一基板访问。
• FXR RECEPTOR AGONIST
  申请人：Xuanzhu (Hainan) Biopharmaceutical Co., Ltd.

  公开号：EP3650449A1

  公开（公告）日：2020-05-13

  The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester, wherein R1, X1, X2, M, Ar, ring A, ring B and L are as defined in the specification. The present invention also relates to: a preparation method for the compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester; a pharmaceutical composition and pharmaceutical formulation containing the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer of the compound, the salt or the ester; and a use of the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer of the compound, the salt or the ester in the preparation of a medicament for treating and/or preventing FXR-mediated diseases.

  本发明属于医药技术领域，尤其涉及一种式（I）化合物、其药学上可接受的盐、其酯或该化合物、该盐或该酯的立体异构体，其中R1、X1、X2、M、Ar、环A、环B和L如说明书中所定义。本发明还涉及：本发明化合物、其药学上可接受的盐、其酯或本发明化合物、盐或酯的立体异构体的制备方法；含有本发明化合物、其药学上可接受的盐、其酯或本发明化合物、盐或酯的立体异构体的药物组合物和药物制剂；以及本发明化合物、其药学上可接受的盐、其酯或本发明化合物、盐或酯的立体异构体在制备治疗和/或预防FXR介导的疾病的药物中的用途。
• FXR agonist
  申请人：XUANZHU BIOPHARMACEUTICAL CO., LTD.

  公开号：US11352358B2

  公开（公告）日：2022-06-07

  The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester, wherein R1, X1, X2, M, Ar, ring A, ring B and L are as defined in the specification. The present invention also relates to: a preparation method for the compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester; a pharmaceutical composition and pharmaceutical formulation containing the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer of the compound, the salt or the ester; and a use of the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer of the compound, the salt or the ester in the preparation of a medicament for treating and/or preventing FXR-mediated diseases.

  本发明属于医药技术领域，具体涉及式(I)所示的化合物、其药学上可接受的盐、酯或该化合物、盐或酯的立体异构体，其中R1、X1、X2、M、Ar、环A、环B和L的定义如说明书中所定义。本发明还涉及:该化合物、其药学上可接受的盐、酯或该化合物、盐或酯的立体异构体的制备方法;包含该化合物、药学上可接受的盐、酯或该化合物、盐或酯的立体异构体的药品组合物和药品制剂;以及该化合物、药学上可接受的盐、酯或该化合物、盐或酯的立体异构体在制备用于治疗和/或预防FXR介导的疾病的药物中的用途。
• [EN] FXR RECEPTOR AGONIST<br/>[FR] AGONISTE DU RÉCEPTEUR FXR<br/>[ZH] FXR受体激动剂
  申请人：XUANZHU PHARMA CO LTD

  公开号：WO2019007418A1

  公开（公告）日：2019-01-10

  本发明属于医药技术领域，具体涉及式(I)所示的化合物、其药学上可接受的盐、其酯或它们的立体异构体，其中，R 1、X 1、X 2、M、Ar、环A、环B、L如说明书中所定义；本发明还涉及所述化合物、其药学上可接受的盐、其酯或它们的立体异构体的制备方法、含有所述化合物、其药学上可接受的盐、其酯或它们的立体异构体的药物组合物和药物制剂，及所述化合物、其药学上可接受的盐、其酯或它们的立体异构体在用于制备治疗和/或预防由FXR受体介导的疾病的药物中的应用。